Clinical Trials: Lowereing A1C, Weight Change & CV Data, HCP

See results from clinical trials with Trulicity when assessed for A1C reduction, weight change and CV risk reduction.

Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial, Cardiovascular Diabetology

The Official Journal of ATTD Advanced Technologies & Treatments for Diabetes Conference Madrid, Spain—February 19–22, 2020

fig3.jpg

Glucose-lowering therapy in patients undergoing percutaneous coronary intervention

T2D Efficacy & Data Jardiance® (empagliflozin) tablets

Model-based Prediction of the Long-term Glucose-Lowering Effects of Ipragliflozin, a Selective Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitor, in Patients with Type 2 Diabetes Mellitus

Nutrients, Free Full-Text

Profile of ipragliflozin for treating type 2 diabetes

PDF) Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV)

Clinical Trials: Lowereing A1C, Weight Change & CV Data, HCP

American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm – 2023 Update - ScienceDirect

Model-based Prediction of the Long-term Glucose-Lowering Effects of Ipragliflozin, a Selective Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitor, in Patients with Type 2 Diabetes Mellitus